Ironwood Pharmaceuticals (IRWD) EBITDA (2010 - 2026)

Ironwood Pharmaceuticals (IRWD) has 17 years of EBITDA data on file, last reported at $72.6 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 349.32% year-over-year to $72.6 million; the trailing twelve-month figure through Mar 2026 stood at $200.2 million (up 277.73% YoY), and the FY2025 full-year result was $98.5 million, up 5.78% from the prior year.
• EBITDA rose to $72.6 million in Q1 2026, from $6.8 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $75.5 million in Q3 2025 to a low of -$1.1 billion in Q2 2023.
• A 5-year average of -$25.3 million and a median of $40.0 million in 2023 frame the typical range for EBITDA.
• Across the five-year window, EBITDA sank 2046.17% in 2023 and soared 349.32% in 2026, its largest moves.
• Tracing IRWD's EBITDA over 5 years: stood at $68.4 million in 2022, then tumbled by 45.02% to $37.6 million in 2023, then retreated by 16.22% to $31.5 million in 2024, then plunged by 78.39% to $6.8 million in 2025, then soared by 966.47% to $72.6 million in 2026.
• Business Quant data shows IRWD's EBITDA at $72.6 million in Q1 2026, $6.8 million in Q4 2025, and $75.5 million in Q3 2025.